NFA
NBIX icon

Nationwide Fund Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Nationwide Fund Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-124,351
Closed -$7.62M – 1337
2017
Q3 		$7.62M Buy
124,351
+3,800
+3% +$201K 0.03% 817
2017
Q2 		$5.54M Sell
120,551
-6,080
-5% -$295K 0.02% 955
2017
Q1 		$5.48M Buy
126,631
+21,922
+21% +$939K 0.02% 944
2016
Q4 		$4.05M Buy
104,709
+53,960
+106% +$2.44M 0.02% 1100
2016
Q3 		$2.57M Buy
50,749
+4,691
+10% +$234K 0.01% 1273
2016
Q2 		$2.09M Sell
46,058
-47,098
-51% -$2.17M 0.01% 1335
2016
Q1 		$3.82M Buy
93,156
+1,272
+1% +$50.5K 0.02% 1072
2015
Q4 		$5.2M Buy
91,884
+18,304
+25% +$930K 0.02% 895
2015
Q3 		$2.93M Sell
73,580
-7,345
-9% -$355K 0.01% 1179
2015
Q2 		$3.87M Buy
80,925
+3,653
+5% +$155K 0.02% 1100
2015
Q1 		$3.07M Buy
77,272
+19,682
+34% +$704K 0.01% 1238
2014
Q4 		$1.29M Sell
57,590
-705
-1% -$13.4K 0.01% 1675
2014
Q3 		$913K Sell
58,295
-205
-0.4% -$3.06K ﹤0.01% 1867
2014
Q2 		$868K Buy
58,500
+4,375
+8% +$61.7K ﹤0.01% 1946
2014
Q1 		$871K Buy
54,125
+2,606
+5% +$44.6K ﹤0.01% 1798
2013
Q4 		$481K Sell
51,519
-1,588
-3% -$15.5K ﹤0.01% 2264
2013
Q3 		$601K Buy
53,107
+2,503
+5% +$34.4K ﹤0.01% 2126
2013
Q2 		$677K Buy
+50,604
New +$622K ﹤0.01% 1868

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Nationwide Fund Advisors's NBIX Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Neurocrine Biosciences (NBIX) in Q4 2017, closing a stake of 124,351 shares — an estimated $7.62M sold.

Nationwide Fund Advisors first reported a position in NBIX in Q2 2013 and held it in 18 quarters. The position peaked at $7.62M in Q3 2017. 267 funds tracked by Wall St. Rank hold NBIX as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Neurocrine Biosciences position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 124,351 Neurocrine Biosciences shares in Q4 2017, an estimated $7.62M.
  • Nationwide Fund Advisors first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 18 quarters.
  • Nationwide Fund Advisors's Neurocrine Biosciences position peaked at $7.62M in Q3 2017.
  • 267 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.